Abera and a non-disclosed party in Europe have initiated a collaboration to design and develop a vaccine candidate against Covid-19 based on Abera’s vaccine delivery platform BERA. The Abera platform works as a plug-and-play system where Abera rapidly can design and produce a prototype vaccine with pre-defined antigens. In this collaboration Abera will design the vaccine candidate and the partner will bring the development forward with pre-clinical trials.
“As the pandemic grows worse we are happy to supply our technology for a very interesting vaccine project where two disruptive technologies meet. Once again we proved that our platform is a true rapid response technology that can produce a prototype vaccine within a few weeks.” says Anders Ericson, CEO at Abera Bioscience